Our Pricing

Understanding the Saxenda Pen: Clinical Use, Dosage, and Patient Outcomes in UK Weight Management

The saxenda pen is a pre-filled liraglutide injection device licensed in the UK for chronic weight management in adults with a BMI of 30 kg/m² or above, or 27 kg/m² with weight-related comorbidities. As a GLP-1 receptor agonist delivered via a convenient multi-dose pen, Saxenda has demonstrated significant weight loss outcomes in clinical trials when combined with a reduced-calorie diet and increased physical activity[1]. At Cured Pharmacy, patients can access the saxenda pen from £48.00 following a free online consultation with our UK-registered prescribers, ensuring safe and clinically appropriate treatment initiation.

How the Saxenda Pen Works for Weight Loss

The saxenda pen delivers liraglutide 6 mg/ml, a glucagon-like peptide-1 (GLP-1) analogue that acts on receptors in the brain to regulate appetite and food intake[1]. By mimicking the action of endogenous GLP-1, this injectable treatment slows gastric emptying, increases feelings of satiety after meals, and reduces overall caloric consumption. Clinical evidence from the SCALE trial programme demonstrated that patients using the saxenda pen alongside lifestyle modification achieved an average weight loss of 8% of initial body weight over 56 weeks, compared to 2.6% with placebo[2].

The multi-dose pen format allows for precise dose titration, starting at 0.6 mg daily and gradually increasing over five weeks to the maintenance dose of 3.0 mg daily. This gradual escalation minimises gastrointestinal side effects commonly associated with GLP-1 therapies, such as nausea and diarrhoea. Each saxenda pen contains 18 mg of liraglutide in 3 ml solution, providing six days of treatment at the maximum 3.0 mg dose. The pen device features a dose counter and requires attachment of a new NovoFine needle for each injection, ensuring sterile administration into subcutaneous tissue of the abdomen, thigh, or upper arm[3].

Saxenda Pen Dosage Schedule and Titration Protocol

Proper dose escalation with the saxenda pen is critical for treatment tolerability and adherence. The recommended titration schedule begins with 0.6 mg once daily for week one, increasing by 0.6 mg increments each week: 1.2 mg in week two, 1.8 mg in week three, 2.4 mg in week four, and reaching the maintenance dose of 3.0 mg from week five onwards[3]. Patients should inject at the same time each day, with or without food, rotating injection sites to prevent lipodystrophy.

If a patient misses a dose of their saxenda pen, it should be administered as soon as remembered within 12 hours of the scheduled time. If more than 12 hours have elapsed, the missed dose should be skipped and the regular schedule resumed the following day. Treatment response should be evaluated after 12 weeks at the 3.0 mg dose—if patients have not lost at least 5% of initial body weight by this point, discontinuation should be considered as they are unlikely to achieve clinically meaningful weight loss with continued therapy[2].

Adjusting Your Saxenda Pen Dose for Side Effects

While the standard saxenda pen titration protocol suits most patients, some individuals experience persistent gastrointestinal symptoms that may require a slower escalation. Our prescribers at Cured Pharmacy can recommend delaying dose increases by an additional week if nausea, vomiting, or diarrhoea persist. However, the dose should not remain below 3.0 mg indefinitely, as clinical efficacy data primarily supports the full maintenance dose. Patients who cannot tolerate 3.0 mg after reasonable titration attempts may not be suitable candidates for liraglutide therapy and should discuss alternative weight management options with their healthcare provider.

Saxenda Pen Storage and Handling Requirements

Unopened saxenda pen devices must be stored in a refrigerator between 2°C and 8°C, protected from light, and never frozen. Once in use, the pen may be stored either in the refrigerator or at room temperature (below 30°C) for up to 30 days. The pen cap should be replaced after each injection to protect the medication from light and prevent contamination. Patients should inspect the solution before each injection—it should appear clear and colourless; any discolouration, cloudiness, or particulate matter indicates the pen should be discarded[4].

When travelling with your saxenda pen, keep it in an insulated cooling pouch if refrigeration is unavailable, and never leave it in direct sunlight or hot vehicles. The pen should not be stored with a needle attached, as this can cause leakage, air bubbles, or blocked needles. Used needles must be disposed of immediately in a sharps container—never recapping them to avoid needlestick injuries. Cured Pharmacy provides comprehensive patient information leaflets with each saxenda pen prescription, detailing proper injection technique, storage guidelines, and disposal procedures in accordance with UK medicines regulations.

Clinical Efficacy of the Saxenda Pen in UK Populations

The saxenda pen has been extensively studied in diverse patient populations through the SCALE clinical trial programme, which enrolled over 5,000 participants across multiple international sites. In the pivotal SCALE Obesity and Prediabetes trial, 63.2% of patients receiving liraglutide 3.0 mg achieved at least 5% weight loss at 56 weeks, compared to 27.1% in the placebo group[2]. More impressively, 33.1% of saxenda pen users lost at least 10% of their initial body weight, a threshold associated with significant improvements in cardiovascular and metabolic risk factors.

Beyond weight reduction, the saxenda pen demonstrated beneficial effects on glycaemic control in patients with prediabetes. Liraglutide treatment reduced the incidence of type 2 diabetes by 79% compared to placebo over the 160-week study period[5]. Additional cardiometabolic improvements included reductions in waist circumference (average 8.2 cm), systolic blood pressure (average 2.8 mmHg), and improvements in lipid profiles. These outcomes position the saxenda pen as a comprehensive weight management intervention rather than merely a cosmetic treatment, particularly for UK patients with obesity-related comorbidities who meet NICE prescribing criteria.

Real-World Saxenda Pen Outcomes in UK Clinical Practice

Post-marketing surveillance and real-world evidence studies in UK primary care settings have generally confirmed the efficacy observed in controlled trials, though with somewhat more modest weight loss outcomes. A retrospective cohort study of 389 patients prescribed the saxenda pen in English GP practices found a mean weight loss of 6.2% at six months among those who remained on treatment[6]. Discontinuation rates were higher than in clinical trials, primarily due to gastrointestinal side effects and cost considerations, highlighting the importance of appropriate patient selection and ongoing support from healthcare professionals throughout the weight management journey.

Saxenda Pen Side Effects and Safety Considerations

The most frequently reported side effects with the saxenda pen affect the gastrointestinal system, occurring in more than 10% of users. These include nausea (experienced by approximately 40% of patients), diarrhoea, constipation, vomiting, and abdominal pain[3]. Most gastrointestinal symptoms are mild to moderate in severity, occur predominantly during the dose escalation phase, and diminish over time as tolerance develops. Eating smaller, more frequent meals and avoiding high-fat foods can help minimise these effects.

More serious but rare adverse events associated with the saxenda pen include pancreatitis, gallbladder disease, and increased heart rate. Patients should be counselled to report severe, persistent abdominal pain radiating to the back, as this may indicate pancreatitis requiring immediate medical assessment. Liraglutide carries a boxed warning in some jurisdictions regarding thyroid C-cell tumours observed in rodent studies, though causality in humans has not been established[4]. The saxenda pen is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. At Cured Pharmacy, our prescribers conduct thorough medical history reviews during the online consultation to identify any contraindications before approving treatment.

Accessing the Saxenda Pen Through Cured Pharmacy

Patients seeking the saxenda pen can complete a confidential online medical assessment at Cured Pharmacy, where our UK-registered prescribers review each case individually to ensure clinical appropriateness. The consultation process takes under three minutes and covers medical history, current medications, weight management goals, and any contraindications to liraglutide therapy. If approved, prescriptions are dispensed from our GPhC-registered pharmacy (9012511) under the supervision of Superintendent Pharmacist Tarun Kumar (GPhC 2233073), with discreet next-day delivery available across the UK.

The saxenda pen is priced from £48.00 at Cured Pharmacy, with first-time patients eligible for £20 off using code Weightlossnew. This represents competitive UK pricing for a licensed weight management treatment that requires ongoing clinical oversight. Each prescription includes comprehensive patient information covering injection technique, dose titration, storage requirements, and when to seek medical advice. Our clinical team remains available via phone (+44 116 4646009) to address any questions or concerns that arise during treatment, ensuring patients receive the support necessary for successful long-term weight management outcomes.

Saxenda Pen Prescription Requirements and Eligibility

The saxenda pen is a prescription-only medicine in the UK, requiring authorisation from a registered prescriber following appropriate clinical assessment. NICE guidelines recommend GLP-1 analogues like liraglutide for weight management only in patients with a BMI of 35 kg/m² or above, or 32.5 kg/m² or above for people from Black, Asian, and other minority ethnic groups who have weight-related comorbidities. Treatment should be continued beyond 12 weeks only if patients achieve at least 5% weight loss, demonstrating treatment response. Our prescribers at Cured Pharmacy apply these evidence-based criteria to ensure the saxenda pen is prescribed safely and appropriately to those most likely to benefit.

Scientific References

1. Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., ... & Lean, M. E. (2009). Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. The Lancet, 374(9701), 1606-1616.
2. Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., ... & Wilding, J. P. (2015). A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine, 373(1), 11-22.
3. Novo Nordisk. (2023). Saxenda 6 mg/ml solution for injection in pre-filled pen: Summary of Product Characteristics. Electronic Medicines Compendium.
4. Medicines and Healthcare products Regulatory Agency. (2023). Liraglutide (Saxenda): reminder of measures to minimise risk of medication errors. Drug Safety Update, 16(8).
5. le Roux, C. W., Astrup, A., Fujioka, K., Greenway, F., Lau, D. C., Van Gaal, L., ... & Wilding, J. P. (2017). 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. The Lancet, 389(10077), 1399-1409.
6. Jensterle, M., Rizzo, M., Haluzik, M., & Janez, A. (2021). Efficacy of GLP-1 RA approved for weight management in patients with or without diabetes: a narrative review. Advances in Therapy, 38(6), 2753-2769.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.